Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

Contrast Agent Substitution to Prevent Repeat Adverse Reactions
McDonald, Jennifer S.

Mayo Clinic

Radiology | July 19, 2022 | Volume: 305 | Issue: 2 | Pages: 350-352

10.1148/radiol.221477 | PMID 35852432 Get It

Machine Learning-Based Fragment Selection Improves the Performance of Qualitative PRM Assays
Vanderboom, Patrick M. , Maus, Anthony , Kemp, Jennifer, Gurtner, Kari M., Grebe, Stefan K. , Pandey, Akhilesh , Dasari, Surendra , Renuse, Santosh , Maus, Anthony D , Madugundu, Anil K. , Kemp, Jennifer V, Pandey, Akhilesh , Singh, Ravinder J.

Mayo Clinic

Journal of Proteome Research | July 18, 2022 | Volume: 21 | Issue: 8 | Pages: 2045-2054

10.1021/acs.jproteome.2c00156 | PMID 35849720 Get It

Hepatology Highlights
Tomlinson, Jennifer L. , Watkins, Ryan , Ilyas, Sumera I. , Ilyas, Sumera Irie , Tomlinson, Jennifer , Penrice, Daniel D. , Ayares, Gustavo , Arab, Juan Pablo

Mayo Clinic

Hepatology | July 16, 2022 | Volume: 76 | Issue: 2 | Pages: 287-288

10.1002/hep.32593 Get It

Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice
Amador, Catalina , Wright, George W. , Weisenburger, Dennis D. , Greiner, Timothy C. , Lone, Waseem , Heavican, Tayla B., Smith, Lynette M. , Pileri, Stefano , Tabanelli, Valentina , Ott, German , Rosenwald, Andreas , Slack, Graham W. , Kim, Won Seog , Hyeh, Young, Li, Yuping , Dong, Gehong, Ondrejka, Sarah L. , Cook, James R. , Lim, Soon Thye , Ong, Choon Kiat , Chapman, Jennifer R. , Raess, Philipp W. , Blombery, Piers , Morris, Stephan W., Staudt, Louis M. , Chan, Wing C. , Iqbal, Javeed , Greiner, Timothy C , Heavican, Tayla B , Smith, Lynette , Pileri, Stefano , Tabanelli, Valentina , Ott, German , Savage, Kerry J , Kim, Won Seog , Hyeh, Young , Song, Joo Y , Ondrejka, Sarah , Cook, James R , Lim, Soon Thye , Ong, Choon Kiat , Inghirami, Giorgio , Raess, Philipp W , Gould, Clare , Jaffe, Elaine S , Vose, Julie , Chan, Wing C , Iqbal, Javeed , Amador, Catalina , Lone, Waseem G , Wright, George , Bouska, Alyssa , Feldman, Andrew L. , Savage, Kerry J. , Ko, Young Hyeh , Song, Joo Y. , Barrionuevo, Carlos , Inghirami, Giorgio , Bhagavathi, Sharathkumar , Gould, Clare , Jaffe, Elaine S. , Rimsza, Lisa M. , Vose, Julie M.

Mayo Clinic

Journal of Clinical Oncology | July 15, 2022 | Volume: 40 | Issue: 36 | Pages: 4261-4275

10.1200/jco.21.02707 | PMID 35839444 Get It

PURPOSE Peripheral T-cell lymphoma (PTCL) includes heterogeneous clinicopathologic entities with numerous diagnostic and treatment challenges. We previously defined robust transcriptomic signatures that distinguish common PTCL entities and identified two novel biologic and prognostic PTCL-not otherwise specified subtypes (PTCL-TBX21 and PTCL-GATA3). We aimed to consolidate a gene expression–based subclassification using formalin-fixed, paraffin-embedded (FFPE) tissues to improve the accuracy and precision in PTCL diagnosis. MATERIALS AND METHODS We assembled a well-characterized PTCL training cohort (n = 105) with gene expression profiling data to derive a diagnostic signature using fresh-frozen tissue on the HG-U133plus2.0 platform (Affymetrix, Inc, Santa Clara, CA) subsequently validated using matched FFPE tissues in a digital gene expression profiling platform (nCounter, NanoString Technologies, Inc, Seattle, WA). Statistical filtering approaches were applied to refine the transcriptomic signatures and then validated in another PTCL cohort (n = 140) with rigorous pathology review and ancillary assays. RESULTS In the training cohort, the refined transcriptomic classifier in FFPE tissues showed high sensitivity (> 80%), specificity (> 95%), and accuracy (> 94%) for PTCL subclassification compared with the fresh-frozen–derived diagnostic model and showed high reproducibility between three independent laboratories. In the validation cohort, the transcriptional classifier matched the pathology diagnosis rendered by three expert hematopathologists in 85% (n = 119) of the cases, showed borderline association with the molecular signatures in 6% (n = 8), and disagreed in 8% (n = 11). The classifier improved the pathology diagnosis in two cases, validated by clinical findings. Of the 11 cases with disagreements, four had a molecular classification that may provide an improvement over pathology diagnosis on the basis of overall transcriptomic and morphological features. The molecular subclassification provided a comprehensive molecular characterization of PTCL subtypes, including viral etiologic factors and translocation partners. CONCLUSION We developed a novel transcriptomic approach for PTCL subclassification that facilitates translation into clinical practice with higher precision and uniformity than conventional pathology diagnosis.
Low Rates of Breakthrough COVID-19 Infection After SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease
Weaver, Kimberly N. , Zhang, Xian , Dai, Xiangfeng , Chen, Wenli , Watkins, Runa , Adler, Jeremy, Dubinsky, Marla C. , Kastl, Arthur , Bousvaros, Athos, Strople, Jennifer , Higgins, Peter , Bewtra, Meenakshi , Bellaguarda, Emanuelle, Craig, Riley, Hernandez, Cristian, Boccieri, Margie , Firestine, Ann M. , Chun, Kelly , Long, Millie D. , Cross, Raymond , Adler, Jeremy, Cross, Raymond K. , Ungaro, Ryan C. , Farraye, Francis A. , Kappelman, Michael D. , Adler, J

Mayo Clinic

Inflammatory Bowel Diseases | July 13, 2022 | Volume: 29 | Issue: 3 | Pages: 483-486

10.1093/ibd/izac138 | PMID 35830416 Get It

Lay SummaryWe demonstrate low rates of breakthrough coronavirus disease 2019 (COVID-19) infection and mild course of illness following severe acute respiratory syndrome coronavirus 2 vaccination in a large cohort of inflammatory bowel disease patients. Residence in southern United States and lower median anti-receptor binding antibody level were associated with development of COVID-19.
Chest wall resection for breast cancer: 21st century Mayo clinic experience
Durgan, Diane M., Thomas, Mathew , Pockaj, Barbara A. , McLaughlin, Sarah A. , Casey, William J., Vijayasekaran, Aparna , Wigle, Dennis A. , Cheville, John C. , Tonneson, Jennifer E., Jakub, James W. , De La Cruz Ku, Gabriel, Wigle, Dennis, Tonneson, Jennifer, Hoskin, Tanya L. , Jakub, James W , Thomas, Mathew , Ku, Gabriel De la Cruz

Mayo Clinic

Journal of Surgical Oncology | July 13, 2022 | Volume: 126 | Issue: 6 | Pages: 962-969

10.1002/jso.27014 | PMID 35830290 Get It

AbstractBackgroundWe hypothesized full‐thickness chest wall resection (FTCWR) with advanced surgical techniques and modern systemic therapy is safe, provides local control, and good overall survival.MethodsRetrospective review of FTCWR (including rib or part of sternum) for breast cancer between 2000 and 2020. Primary endpoints included 90‐day morbidities and all‐cause mortality. Secondary endpoints were loco‐regional and distant recurrence, DFS and overall survival (OS).ResultsA total of 35 patients met the criteria. 34 FTCWR were for recurrence and the median time to chest wall recurrence was 6 years. Tumor subtype was triple‐negative in 51% and the remainder HR+ Her2−. 58% were palliative resections. FTCWR included rib(s) in 89% and portion of sternum in 57%; 94% required reconstruction and 80% were R0 resections. There were no 90‐day mortalities. Overall morbidity was 10/35(28%). 17(49%) patients received neoadjuvant systemic therapy for their recurrence and three received neoadjuvant radiation. Adjuvant treatment included chemotherapy (8), endocrine therapy (3), and both (8). Ten patients (28%) received adjuvant radiation. The Median follow‐up was 31 months and there were 6 (17%) loco‐regional and 7 (20%) distant recurrences. OS was 86% and 67% at 1 and 3 years, respectively.ConclusionFTCWR was associated with low morbidity, mortality, recurrence rates, and good OS. Selective FTCWR is safe and has acceptable short‐term survival rates.
Cocultured Schwann Cells Rescue Irradiated Pelvic Neuron Outgrowth and Increase Survival
Randolph, Joshua T., Pak, Elena S. , McMains, Jennifer C., Hannan, Johanna L. , Koontz, Bridget F.

Mayo Clinic

The Journal of Sexual Medicine | July 13, 2022 | Volume: 19 | Issue: 9 | Pages: 1333-1342

10.1016/j.jsxm.2022.06.008 | PMID 35840531 Get It

ABSTRACTBackgroundProstatic radiation therapy (RT) leads to erectile dysfunction by damaging peri-prostatic pro-erectile nerves of the pelvic ganglion. Schwann cells (SC) facilitate neuronal repair after mechanical injury, however, their role in repair of pelvic neurons post-radiation hasn’t been explored.AimTo determine if SCs cocultured with primary pelvic neurons can rescue neuronal survival and growth after ex vivo RT.MethodsMajor pelvic ganglia (MPG) were collected from adult male Sprague-Dawley rats (n = 12) to isolate SCs. SCs received RT (0 or 8 Gy), were plated on coated coverslips and grown to confluence before the addition of neurons. Additional MPGs were irradiated (0 or 8 Gy) and digested to isolate pelvic neurons. Dissociated neurons were plated alone or atop SC-coated coverslips to create 6 experimental groups (n = 3/grp): (i) Control (CON) MPG, (ii) RT MPG, (iii) CON SC + CON MPG, (iv) CONSC + RT MPG, (v) RT SC + CON MPG, and (iv) RT SC + RT MPG. After 72 hours, coverslips were fixed and stained for beta-tubulin (neuron marker), S100 (SC marker), neuronal nitric oxide synthase (nitrergic marker), tyrosine hydroxylase (sympathetic marker), and terminal deoxynucleotidyl transferase dUTP nick-end labeling.OutcomesWe measured neurite length, branching, specific neuron populations and apoptosis.ResultsEx vivo RT decreased MPG neuron length, increased apoptosis and decreased nitrergic neurons in monoculture. Compared to all other groups, CON SC + RT MPG cocultures demonstrated increased neurite outgrowth (P < .001). Neurite branching was decreased in the RT MPG + RT SC coculture, but unchanged in other cocultures. Groups containing RT MPG neurons exhibited increased apoptosis, but coculture with CON SC reduced the degree of RT-induced apoptosis (P < .01). The number of tyrosine hydroxylase positive neurons was unchanged while nitrergic neurons were significantly lower in RT neurons and coculture with CON SCs was unable to prevent nitrergic loss.Clinical TranslationThese findings suggest that SCs may be an important target in prostate cancer patients with radiation-induced pelvic neuropathy to promote MPG neuron survival and neuronal repair after RT.Strengths and LimitationsThis is the first study to characterize the ex vivo ability of SCs to rescue pelvic nerve growth and survival. The study is limited by little supporting mechanistic molecular data and the need to confirm the ability of healthy SCs to promote pelvic neuron survival and repair following prostatic RT in vivo.ConclusionUnirradiated SCs partially mitigated RT-induced MPG apoptosis but did not affect the loss of nitrergic neuron populations suggesting that SCs promote irradiated MPG neuron survival and facilitate intrinsic repair functions.
Prevalence and clinical characteristics of age-related distance esotropia
Claxton, Matthew R., Bang, Genie M., Martinez‐Thompson, Jennifer M. , Hodge, David O. , Mohney, Brian G., Martinez-Thompson, Jennifer, Claxton, Matthew R.

Mayo Clinic

Strabismus | July 8, 2022 | Volume: 30 | Issue: 3 | Pages: 115-120

10.1080/09273972.2022.2097707 | PMID 35799374 Get It

Design and validation of a FHIR-based EHR-driven phenotyping toolbox
Brandt, Pascal , Pacheco, Jennifer A. , Adekkanattu, Prakash , Sholle, Evan , Stone, Daniel J. , Knaack, David, Xu, Zhenxing , Wang, Fei , Jiang, Guoqian , Pathak, Jyotishman , Brandt, Pascal S , Sholle, Evan T , Knaack, David M, Peng, Yifan , Benda, Natalie C , Luo, Yuan , Rasmussen, Luke V , Pacheco, Jennifer A , Abedian, Sajjad , Xu, Jie , Luo, Yuan , Rasmussen, Luke V.

Mayo Clinic

Journal of the American Medical Informatics Association | July 8, 2022 | Volume: 29 | Issue: 9 | Pages: 1449-1460

10.1093/jamia/ocac063 | PMID 35799370 Get It

Abstract Objectives To develop and validate a standards-based phenotyping tool to author electronic health record (EHR)-based phenotype definitions and demonstrate execution of the definitions against heterogeneous clinical research data platforms. Materials and Methods We developed an open-source, standards-compliant phenotyping tool known as the PhEMA Workbench that enables a phenotype representation using the Fast Healthcare Interoperability Resources (FHIR) and Clinical Quality Language (CQL) standards. We then demonstrated how this tool can be used to conduct EHR-based phenotyping, including phenotype authoring, execution, and validation. We validated the performance of the tool by executing a thrombotic event phenotype definition at 3 sites, Mayo Clinic (MC), Northwestern Medicine (NM), and Weill Cornell Medicine (WCM), and used manual review to determine precision and recall. Results An initial version of the PhEMA Workbench has been released, which supports phenotype authoring, execution, and publishing to a shared phenotype definition repository. The resulting thrombotic event phenotype definition consisted of 11 CQL statements, and 24 value sets containing a total of 834 codes. Technical validation showed satisfactory performance (both NM and MC had 100% precision and recall and WCM had a precision of 95% and a recall of 84%). Conclusions We demonstrate that the PhEMA Workbench can facilitate EHR-driven phenotype definition, execution, and phenotype sharing in heterogeneous clinical research data environments. A phenotype definition that integrates with existing standards-compliant systems, and the use of a formal representation facilitates automation and can decrease potential for human error.